The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Director/PDMR Shareholding

18 Mar 2020 07:49

RNS Number : 5885G
4d Pharma PLC
18 March 2020
 

 

 The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

4D pharma plc

(the "Company" or "4D")

PDMR Dealings

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, is pleased to announce that David Norwood (the "Director") has purchased ordinary shares in the Company as listed below. Following this transaction, the Director has a resulting interest in the ordinary shares of the Company as listed below.

Name

Shares in 4D pharma plc before purchase

% of total shares in issue

Shares in 4D pharma plc after purchase

% of total shares in issue

David Norwood (Chairman)

8,457,061

7.7%

 8,557,061

7.8%

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

David Norwood

2

Reason for the notification

a)

Position/status

Chairman/ PDMR

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

4D Pharma plc

b)

LEI

213800O49VYSXWE2ZD52

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of £0.0025

 

ISIN: GB00BJL5BR07

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 Price(s)

Volume(s)

28p

100,000

d)

Aggregated information

- Aggregated volume

- Price

 

N/A

 

e)

Date of the transaction

17th March 2020

f)

Place of the transaction

London Stock Exchange, AIM

 

 

For further information please contact:

4D

Duncan Peyton, Chief Executive Officer

ir@4dpharmaplc.com

+ 44 (0)113 895 0130

 

 

N+1 Singer - Nominated Adviser and Joint Broker

+44 (0) 20 7496 3000

Aubrey Powell / Justin McKeegan / Alex Bond (Corporate Finance)

Tom Salvesen (Corporate Broking)

 

Bryan Garnier & Co. Limited - Joint Broker

+44 (0)20 7332 2500

Dominic Wilson / Phil Walker

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHEAXDPFLKEEEA

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.